airinspace’s HEPA MD® airborne elimination technology has become the benchmark in bone marrow transplant units. It has been internationally validated by numerous independent laboratories. It has been selected by most university hospitals in France, in particular to prevent infections in immunocompromised patients in haematology, bone marrow and solid organ transplant units or ICU.
Originally developed for air treatment in MIR and ISS space stations, the HEPA-MD® elimination technology was patented by airinspace and applied to the specific requirements of the hospital environment:
The HEPA-MD® reactor developed by airinspace combines the effectiveness of 4 air handling technologies on a number of levels: